Palladiumand radical-mediated cyclizations from N-(2-bromoprop-2-enyl)-1-azaspiro[4.5]decanes were studied, leading to the formation of azatricyclic derivatives embodying 7,10a-methanopyrrolo[1,2-a]azocine or a pyrrolo [2,3-i]indole framework depending on the reaction conditions
Introduction
The immunosuppressant FR901483 (Scheme 1) was isolated by a Fujisawa group in 1996, 1,2 who determined the structure by X-ray crystallography and the absolute configuration was eventually assigned when Snider achieved the enantiocontrolled total synthesis in 1999. 3 From a structural point of view, the most conspicuous feature of FR901483 is an azatricyclic ring system consisting of the combined morphan and indolizine nuclei sharing the piperidine ring. In recent years several groups have succeeded in synthesizing the FR901483. [3] [4] [5] [6] [7] [8] Four of them (Snider, 3 Sorensen, 4 Ciufolini, 5 and Brummond 6 ) achieved the enantioselective synthesis of the natural enantiomer, while Funk's 7 and Fukuyama's 8 syntheses were developed in the racemic series. In all reported routes, a functionalized 1-azaspiro [4.5] decan-8-one was used as an intermediate to build the azatricyclic core of the target, using an aldol process whose regioselectivity is sensitive to the substitution pattern and reaction conditions. With the aim of approaching the FR901483 framework 10 through a regioselective ring closure from an azaspiro [4.5] decan-8-one, we decided to prepare the azaspiranic enone 1 with the idea of forming the bridge either on the carbonyl α' position, the double bond acting as a blocking group (path a) or on the double bond, after reduction of the enone group, (path b) (Scheme 1). In the 
Results and Discussion
To access the tricyclic skeleton of FR901483 through the proposed methodology we required a cyclization precursor embodying the 1-azaspiro [4.5] dec-6-en-8-one framework (i.e. 1). Although we have recently described an approach to obtain compounds of this type in their enantiopure form, 13 for this study we prepared compound 1 in its racemic form. Our protocol to assemble this azabicyclic system was inspired by Kawahara and Nagumo's procedure 14 for preparing spirolactams from proline derivatives, based on the alkylation of a proline derivative followed by some functional group interconversion steps and a final aldol cyclization step. The synthesis (Scheme 2) starts with the alkylation of the L-proline derivative 2 with 4-bromo-1-butene using 1.15 eq of LDA to afford racemic 3 (64%). 15 The synthetic sequence 3 ∏ 6 involves conversion of ester 3 to aldehyde 5 through a reduction-oxidation process, followed by Wacker oxidation of the terminal alkene to give the keto aldehyde 6. Aldol condensation and succesive elimination process in the ketol intermediate gave cyclohexenone 16 In the latter case the reaction evolved through a Heck reductive process. The two compounds formed were separated and their structure elucidated by 2D NMR spectra (see Table 1 ). Scheme 3. Palladium-and tributylstannane-promoted cyclization of vinyl bromides 7 and 11.
Although this ring-forming reaction led to the azatricyclic compound 8 and constitutes a novel approach to the heterocyclic system found in FR901483, the low regioselectivity (2 to 1) together with the poor yield in the synthesis of the bridged azatricyclic compound, via the intramolecular palladium-catalyzed enolate-driven cross coupling between the vinyl halide and the enone, induced us to discard this approach. Thus we turned our attention to Path b using the same azaspiranic intermediate 1.
As we mentioned before, we were curious to see if a radical process from vinyl bromide 11 through a homoallyl-cyclopropylmethyl radical could be an entry to the FR901483 framework. Reduction of enone 1 with NaBH 4 /CeCl 3 stereoselectively gave the allylic alcohol 10, which after deprotection and alkylation with 2,3-dibromopropene provided the radical precursor 11. Subjection of the vinyl bromide 11 to standard tin hydride conditions promoted only the 5-exo radical cyclization to give 12, no bridged product E being observed (Scheme 4).
The course of the reaction may be influenced by steric factors. Indeed, the vinyl radical initially formed from the conformationally mobile 11 could lead to two conformationally different homoallyl radicals (A and B), but only homoallyl radical B could evolve to afford the cyclopropylmethyl radical (B ∏ C process) required for the formation of the six-membered ring intermediate D, from which E could be obtained.
Considering that the only conformation detected for compound 12 was that corresponding to a trans-diequatorial conformational relationship between the hydroxyl group and the nitrogen atom, as suggested by the NMR experiments (Table 1) , we assumed the same conformation for its radical precursor A. This may suggest that one of the reasons for the non-formation of compound E is the inaccessibility of the correct chair conformation B in the first radical formed. In turn, the lack of reactivity in the homoallyl radical A to the corresponding rearranged radical is due to steric reasons, as the conformation depicted in Scheme 4 shows, and to the fact that a conformational change to B is not available in the time-scale of the radical processes. Table 1 shows the NMR data of the three azatricyclic compounds reported here. Comparison of the NMR values of protons and carbons in the C(3)-C(5)-C(10a) domain reveals significant differences (Table 1) . Most notably, the spirane carbon C-10a of the bridged compound 8 resonates at δ 58.3, whereas that of fused compounds 9 and 12 appears at δ 71.6. Assignments were arded by gCOSY, gHSQC, and gHMBC spectra.
The relative configuration of 12 was inferred from the pattern of the two methine proton coupling constants of the stereogenic carbons at C-6a and C-8.
In summary, although the attempts to introduce a regioselective formation of the FR901483 azatricyclic framework have not been very fruitful, the easy formation of the tricyclic system of perhydropyrrolo [2,1- 
tert-Butyl 2-methyl 2-(But-3-enyl)pyrrolidine-1,2-dicarboxylate (3).
To a solution of diisopropylamine (4.21 mL, 30.1 mmol) in THF (100 mL) was added at -78 ºC n-BuLi (1.6 M in hexanes, 20 mL, 32.1 mmol) dropwise and the mixture was stirred at this temperature for 10 min. A solution of 2 (5.94 g, 25.9 mmol) and HMPA (20 mL, 129.6 mmol) in THF (30 mL) was added via cannula and stirring was continued for a further 30 min. 4-bromo-1-butene (7.2 g, 51.8 mmol) was added dropwise at -78 ºC and the mixture was allowed to reach rt while stirring overnight. The reaction mixture was quenched with a saturated aqueous NH 4 Cl (50 mL) and extracted with ether (3×50 mL). The combined organic extracts were washed with brine (3×50 mL), dried, concentrated and purified by chromatography (hexane/EtOAc 4:1 to 1:1) yielding 3 as a viscous colorless oil (4.7 g, 64% 
tert-Butyl 2-Formyl-2-(3-oxobutyl)pyrrolidine-1-carboxylate (6).
A mixture of CuCl (0.29 g, 2.9 mmol), PdCl 2 (0.138 g, 0.78 mmol), water (1 mL) and DMF (15 mL) was stirred at rt and under an oxygen atmosphere for 1 h. To the resulting mixture was added a solution of aldehyde 5 (0.70 g, 2.8 mmol) in DMF (15 mL) and stirring at rt under oxygen was prolonged for a further 5 h. The mixture was quenched by the addition of saturated aqueous NaHCO 3 (10 mL), saturated aqueous NH 4 Cl (10 mL) and extracted with ether/hexane (1:1 300 mL). The organics were washed with brine, dried and concentrated to yield keto aldehyde 6 (0.6 g, 81%) pure enough to be used in the next step without further purification. An analytical sample was obtained by chromatography (hexane/AcOEt 9:1). The NMR data of 6 coincide with those reported for this compound when it was synthesized in an enantiopure form using another methodology. 
1-(2-Bromoprop-2-enyl)-1-azaspiro[4.5]dec-6-en-8-one (7).
A mixture of 1 (0.23 g, 0.92 mmol) and TFA (2.87 mL, 37.2 mmol) in CH 2 Cl 2 (9 mL) was stirred at rt for 2 h prior to solvent evaporation. The residue was taken up in 10 mL of CH 3 CN and 2,3-dibromopropene (0.16 mL, 1.40 mmol), K 2 CO 3 (0.39 g, 2.79 mmol) and LiI (0.013 g, 0.09 mmol) were added. The resulting mixture was heated overnight at 60 ºC, quenched with water (5 mL) and extracted with CH 2 Cl 2 (5×25 mL). The organic extracts were dried, concentrated and the residue purified by chromatography (CH 2 Cl 2 ) to give pure compound 7 as a viscous yellowish oil (0.147 g, 60% Methylene-2,3,4,5,6,7-hexahydro-1H,10aH-7,10a-methanopyrrolo[1,2-a]azocin-8-one (8) .
To a solution of 7 (35 mg, 0.13 mmol) in THF (5 mL) were added phenol (37 mg, 0.39 mmol), tBuOK solution (1 M in butanol, 0.32 mL, 0.32 mmol) and Pd(PPh 3 ) 4 (30 mg, 0.026 mmol). The resulting mixture was refluxed overnight, then diluted with CH 2 Cl 2 (25 mL) and washed with saturated aqueous NaHCO 3 , aqueous NaOH (2M) and brine. The organics were dried, concentrated and the residue purified by chromatography on Al 2 O 3 (activity II-III, 70-230 mesh) eluting from hexane to 7:3 hexane/EtOAc to give 8 (5.1 mg, 21%) followed by 9 (3 mg, 12%). To a solution of enone 1 (100 mg, 0.40 mmol) in THF (10 mL) at 0 ºC was added CeCl 3 (125 mg, 0.5 mmol) and the mixture was stirred for 5 min. NaBH 4 (20 mg, 0.5 mmol) was added and stirring was continued for 5 min at 0 ºC and 10 min at rt. The reaction mixture was evaporated to dryness, water (10 mL) was added and the mixture extracted with CHCl 3 . The combined organic extracts were dried and concentrated. 
